Immunomodulation Effects of <i>Schizonepeta tenuifolia</i> Briq. on the IgE‐Induced Allergic Model of RBL‐2H3 Cells

Lin, Yi‐Hsuan; Chen, Hsing-Yu; Chiu, Jung-Hui; Chen, Kun-Jei; Ho, Hung‐Yao; Yang, Sien-Hung

doi:10.1155/2018/6514705

Cited by 11 publications

(8 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Inhalable microparticles of Lonicera japonica decrease the levels of tumor necrosis factor-α and interleukin-6 in bronchoalveolar fluid and inflammatory cells in peripheral blood, induce recovery of elastin and collagen distribution, and reduce caspase-3 expression in lung tissue (24). Schizonepeta tenuifolia suppresses immunoglobulin E-induced allergic reactions at the cellular level, and ameliorates inflammatory cytokines and eosinophilic inflammation (25,26). These results suggest that HX110 can prevent the development of chronic airway disease that occurs as chronic inflammation persists.…”

Section: Discussionmentioning

confidence: 81%

Efficacy and safety of HX 110-A and HX 110-B in promoting respiratory health: protocol for an 8-week, randomized, double-blind, parallel group, placebo-controlled trial

Lee

et al. 2020

Ann Palliat Med

View full text Add to dashboard Cite

Background: HX110-A and HX110-B are compound extracts based on radix adenophorae and rhizoma dioscoreae, respectively, which have anti-inflammatory activity. There are limited data on whether they may help improve respiratory conditions including lung function. Therefore, in this trial, we will evaluate the effectiveness and safety of the use of HX110-A and HX110-B for the treatment of respiratory health in adults with mild respiratory symptoms.Methods: This will be an 8-week, randomized, double-blind, parallel group, placebo-controlled trial with three arms. Adults more than 40 years old with persistent respiratory symptoms will be enrolled. Patients with definite respiratory disease or with a history of recent intake of antioxidants or anti-inflammatory agents will be excluded. Study subjects will be assigned at a 1:1:1 ratio into the following three arms: controls, experimental group 1 (HX110-A), and experimental group 2 (HX110-B). Control or experimental foods will be administered for 8 weeks, and follow-up will be up to 12 weeks. The primary outcome will be total antioxidant capacity. Secondary outcomes will be inflammatory indexes, respiratory symptoms, lung function, quality of life, and fatigue level. Safety outcomes will be assessed by monitoring adverse events and vital signs, and through clinical pathology tests.Discussion: This trial will reveal the effectiveness and safety of HX110-A and/or HX110-B for medical purposes in adults with respiratory symptoms. The results should clarify if active intake of specific foods with these functional compounds may promote respiratory health in adults without definite respiratory disease.

show abstract

Section: Discussionmentioning

confidence: 81%

Efficacy and safety of HX 110-A and HX 110-B in promoting respiratory health: protocol for an 8-week, randomized, double-blind, parallel group, placebo-controlled trial

Lee

et al. 2020

Ann Palliat Med

View full text Add to dashboard Cite

show abstract

“…On the other hand, Schizonepeta tenuifolia demonstrated a significant reduction (P < 0.05) of IFN-γ, IL-4 and IL-13 in IgE-induced allergic model of RBL-2H3 cells with 100 µg/ml of aqueous extract. In the same study, S. tenuifolia aqueous extract showed no cytotoxicity even at a higher concentration up to 1,000 µg/ml (Lin et al, 2018). However, a more thorough and detailed toxicological investigation is required to develop a more evidence-based safety profile.…”

Section: Regulation Of T Cell Responsesmentioning

confidence: 86%

Lamiaceae: An Insight on Their Anti-Allergic Potential and Its Mechanisms of Action

2019

View full text Add to dashboard Cite

The prevalence of allergic diseases such as asthma, allergic rhinitis, food allergy and atopic dermatitis has increased dramatically in recent decades. Conventional therapies for allergy can induce undesirable effects and hence patients tend to seek alternative therapies like natural compounds. Considering the fact above, there is an urgency to discover potential medicinal plants as future candidates in the development of novel anti-allergic therapeutic agents. The Lamiaceae family, or mint family, is a diverse plant family which encompasses more than 7,000 species and with a cosmopolitan distribution. A number of species from this family has been widely employed as ethnomedicine against allergic inflammatory skin diseases and allergic asthma in traditional practices. Phytochemical analysis of the Lamiaceae family has reported the presence of flavonoids, flavones, flavanones, flavonoid glycosides, monoterpenes, diterpenes, triterpenoids, essential oil and fatty acids. Numerous investigations have highlighted the anti-allergic activities of Lamiaceae species with their active principles and crude extracts. Henceforth, this review has the ultimate aim of compiling the up-to-date (2018) findings of published scientific information about the anti-allergic activities of Lamiaceae species. In addition, the botanical features, medicinal uses, chemical constituents and toxicological studies of Lamiaceae species were also documented. The method employed for data collection in this review was mainly the exploration of the PubMed, Ovid and Scopus databases. Additional research studies were obtained from the reference lists of retrieved articles. This comprehensive summarization serves as a useful resource for a better understanding of Lamiaceae species. The anti-allergic mechanisms related to Lamiaceae species are also reviewed extensively which aids in future exploration of the anti-allergic potential of Lamiaceae species.

show abstract

“…Spica Schizonepetae is first recorded in the Shennong's Classic of Materia Medica, an ancient classic book in the traditional Chinese medicine (TCM). It possesses various pharmacologica activities, such as antitumor, anti-inflammation, analgesic, anti-virus, and bacteriostasis [2][3][4]. In clinical research, Spica Schizonepetae or the ancient Chinese medicine formulas with Spica Schizonepetae as the main medicine (like Zhisou powder, Yinqiao powder and some empirical formulas), have also been used to treat lung cancer and the related diseases [5].…”

Section: Introductionmentioning

confidence: 99%

Interpretation of the absorbed constituents and pharmacological effect of Spica Schizonepetae extract on non-small cell lung cancer

et al. 2021

View full text Add to dashboard Cite

As a traditional Chinese medicine (TCM) with a usage history of over 2,000 years in China, Spica Schizonepetae possesses definite clinical activity in the treatment of non-small cell lung cancer (NSCLC). However, its active ingredients and mechanism of action remain unclear at present. The further exploration of its active components and underlying mechanism will provide a basis for the development of candidate anti-tumor drugs. Our previous study explored the chemical constituents of Spica Schizonepetae extract (SSE). On this basis, molecular networking technology was applied in analyzing the QTOF-MS/MS data of rat plasma after intragastric administration of SSE using the GNPS database platform. A total of 26 components were found, including 9 proterotype components and 17 metabolites, which revealed the potential active ingredients of SSE. Later, the Lewis lung cancer mouse model was established, and the inhibition rate and histopathological sections were used as the indicators to investigate the anti-tumor effect of SSE, whereas the body weight, survival rate, thymus index and spleen index served as the indicators to explore the pharmacological effects of SSE on improving mouse immunity. The results showed that SSE had comparable anti-tumor efficacy to cisplatin, which enhanced the immunity, improved the quality of life, and extended the survival time of lung cancer mice. Furthermore, human A549 lung tumor cells were selected to explore the mechanism of SSE in treating NSCLC based on cell metabonomics. After data mining by the MPP software, 23 differential endogenous metabolites were identified between SSE and tumor groups. Moreover, results of pathway enrichment analysis using the MetaboAnalyst 4.0 software indicated that these metabolites were mainly enriched in four metabolic pathways (p < 0.1). By adopting the network pharmacology method, the metabolic pathways discovered by cell metabolomics were verified against the ChEMBL, STITCH, UniProt and TCGA databases, and differences in the underlying mechanism between cells and humans were found. It was proved that SSE affected the metabolism of purine, arachidonic acid and histidine to exert the anti-tumor efficacy. Furthermore, the multi-target, multi-pathway, and immunoenhancement mechanism of SSE in anti-tumor treatment was revealed, which provided a scientific basis for new drug development and the rational application of Spica Schizonepetae in clinic.

show abstract

Immunomodulation Effects of Schizonepeta tenuifolia Briq. on the IgE‐Induced Allergic Model of RBL‐2H3 Cells

Cited by 11 publications

References 40 publications

Efficacy and safety of HX 110-A and HX 110-B in promoting respiratory health: protocol for an 8-week, randomized, double-blind, parallel group, placebo-controlled trial

Efficacy and safety of HX 110-A and HX 110-B in promoting respiratory health: protocol for an 8-week, randomized, double-blind, parallel group, placebo-controlled trial

Lamiaceae: An Insight on Their Anti-Allergic Potential and Its Mechanisms of Action

Interpretation of the absorbed constituents and pharmacological effect of Spica Schizonepetae extract on non-small cell lung cancer

Contact Info

Product

Resources

About